castration

Summary

Summary: Surgical removal or artificial destruction of gonads.

Top Publications

  1. ncbi Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
    Johann S de Bono
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
    Clin Cancer Res 14:6302-9. 2008
  2. pmc Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
    Yingming Li
    Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cancer Res 73:483-9. 2013
  3. pmc EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent
    Kexin Xu
    Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Science 338:1465-9. 2012
  4. ncbi Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Lancet Oncol 13:983-92. 2012
  5. pmc The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration
    Jichao Qin
    Department of Molecular Carcinogenesis, University of Texas M D Anderson Cancer Center, Science Park, Smithville, TX 78957, USA
    Cell Stem Cell 10:556-69. 2012
  6. pmc A luminal epithelial stem cell that is a cell of origin for prostate cancer
    Xi Wang
    Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Nature 461:495-500. 2009
  7. pmc Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer
    Rong Hu
    Department of Urology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Res 72:3457-62. 2012
  8. pmc Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e27970. 2011
  9. ncbi Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    Gerhardt Attard
    Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 26:4563-71. 2008
  10. ncbi Chemotherapy-based treatment for castration-resistant prostate cancer
    Bostjan Seruga
    Institute of Oncology Ljubljana, Ljubljana, Slovenia
    J Clin Oncol 29:3686-94. 2011

Detail Information

Publications318 found, 100 shown here

  1. ncbi Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
    Johann S de Bono
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
    Clin Cancer Res 14:6302-9. 2008
    ..prospective study was to establish the relationship between posttreatment CTC count and overall survival (OS) in castration-resistant prostate cancer (CRPC)...
  2. pmc Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
    Yingming Li
    Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cancer Res 73:483-9. 2013
    ..receptor (AR) transcriptional activity underlies resistance to AR-targeted therapy and progression to lethal castration-resistant prostate cancer (CRPC)...
  3. pmc EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent
    Kexin Xu
    Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Science 338:1465-9. 2012
    ..We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor...
  4. ncbi Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Lancet Oncol 13:983-92. 2012
    Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study...
  5. pmc The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration
    Jichao Qin
    Department of Molecular Carcinogenesis, University of Texas M D Anderson Cancer Center, Science Park, Smithville, TX 78957, USA
    Cell Stem Cell 10:556-69. 2012
    ..robust tumor development and resist androgen ablation in castrated hosts, and they harbor highly tumorigenic castration-resistant PCa cells that can be prospectively enriched using ALDH(+)CD44(+)α2β1(+) phenotype...
  6. pmc A luminal epithelial stem cell that is a cell of origin for prostate cancer
    Xi Wang
    Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Nature 461:495-500. 2009
    ..lineage-marking demonstrates that rare luminal cells that express Nkx3-1 in the absence of testicular androgens (castration-resistant Nkx3-1-expressing cells, CARNs) are bipotential and can self-renew in vivo, and single-cell ..
  7. pmc Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer
    Rong Hu
    Department of Urology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Res 72:3457-62. 2012
    Continued androgen receptor (AR) signaling is an established mechanism underlying castration-resistant prostate cancer (CRPC), and suppression of androgen receptor signaling remains a therapeutic goal of CRPC therapy...
  8. pmc Androgen receptor variants occur frequently in castration resistant prostate cancer metastases
    Xiaotun Zhang
    Department of Urology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e27970. 2011
    Although androgens are depleted in castration resistant prostate cancer (CRPC), metastases still express nuclear androgen receptor (AR) and androgen regulated genes...
  9. ncbi Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    Gerhardt Attard
    Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 26:4563-71. 2008
    Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling...
  10. ncbi Chemotherapy-based treatment for castration-resistant prostate cancer
    Bostjan Seruga
    Institute of Oncology Ljubljana, Ljubljana, Slovenia
    J Clin Oncol 29:3686-94. 2011
    Most men with metastatic prostate cancer respond to various types of androgen ablation but progress to castration-resistant disease...
  11. pmc Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
    Philip A Watson
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:16759-65. 2010
    ..are detected in normal and malignant human prostate tissue, with the highest levels observed in late stage, castration-resistant prostate cancer...
  12. pmc Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
    John C Araujo
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:63-71. 2012
    To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (PC), the authors conducted a phase 1-2 trial combining docetaxel with dasatinib, an oral SRC ..
  13. ncbi Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically
    Charles J Ryan
    UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, San Francisco, CA 94115, USA
    J Clin Oncol 29:3651-8. 2011
    Discoveries over the past decade suggest that castration-resistant prostate cancer (CRPC) is sensitive, but not resistant to, further manipulation of the androgen-androgen receptor (AR) axis...
  14. ncbi Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer
    Markus Germann
    Department of Urology, University of Bern, Bern, Switzerland
    Stem Cells 30:1076-86. 2012
    b>Castration is the standard therapy for advanced prostate cancer (PC). Although this treatment is initially effective, tumors invariably relapse as incurable, castration-resistant PC (CRPC)...
  15. ncbi Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941
    Charles Huggins
    J Urol 167:948-51; discussion 952. 2002
  16. ncbi A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
    Robert W Ross
    Division of Solid Tumor Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 13:1105-13. 2012
    Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer.
  17. pmc Mechanisms mediating androgen receptor reactivation after castration
    Xin Yuan
    Cancer Biology Program, Hematology Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Urol Oncol 27:36-41. 2009
    ..invariably relapse with a more aggressive form of PCa termed hormone refractory, androgen independent, or castration resistant PCa (CRPC)...
  18. pmc Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
    Kai Hsiung Chang
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Proc Natl Acad Sci U S A 108:13728-33. 2011
    ..The response is usually transient, and metastatic tumors almost invariably eventually progress as castration-resistant prostate cancer (CRPC)...
  19. ncbi Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy
    Erica S Chevalier-Larsen
    Department of Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Neurosci 24:4778-86. 2004
    ..The elimination of androgens by surgical castration of severely affected, aged 112Q male mice partially restored motor function as well as NF-H levels...
  20. ncbi In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors
    Robert Snoek
    Prostate Center at Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, British Columbia, Canada
    Clin Cancer Res 15:39-47. 2009
    Progression to the castration-resistant state is the incurable and lethal end stage of prostate cancer, and there is strong evidence that androgen receptor (AR) still plays a central role in this process...
  21. ncbi Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
    G Sonpavde
    US Oncology Research, Inc, Houston, TX, USA
    Ann Oncol 21:319-24. 2010
    Systemic therapy options are limited for metastatic castration-resistant prostate cancer (CRPC) patients who progress following docetaxel (Taxotere)...
  22. pmc HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer
    Junkui Ai
    Department of Urology, University of Pittsburgh School of Medicine, Pennsylvania 15232, USA
    Mol Endocrinol 23:1963-72. 2009
    The development of castration-resistant prostate cancer (PCa) requires that under castration conditions, the androgen receptor (AR) remains active and thus nuclear...
  23. ncbi Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
    David Olmos
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Lancet Oncol 13:1114-24. 2012
    ..We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.
  24. ncbi Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer
    Ai Chiin Lim
    Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, United Kingdom
    Curr Drug Targets 14:408-19. 2013
    The growth and dependence of Prostate Cancer (PCa) on androgen stimulation led to the use of castration to reduce circulating levels of androgens and anti-androgens to directly target the androgen receptor (AR) ligand-binding domain (LBD)...
  25. pmc Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4526-31. 2008
    ..We now report survival analyses at 6.5 years from the initiation of therapy with a median potential follow-up of 4.4 years...
  26. pmc Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
    Tanya B Dorff
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Clin Cancer Res 16:3028-34. 2010
    Interleukin-6 (IL-6) facilitates cancer cell survival via pleotrophic effects. We conducted a multicenter phase II study of CNTO328 (siltuximab) as second-line therapy for men with castration-resistant prostate cancer.
  27. ncbi Docetaxel-based combination therapy for castration-resistant prostate cancer
    M D Galsky
    Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA
    Ann Oncol 21:2135-44. 2010
    Once castration resistance is documented and secondary hormone therapy is ineffective, standard treatment of metastatic prostate cancer is docetaxel, with bisphosphonates and radiopharmaceuticals administered to treat bone symptoms...
  28. ncbi All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer
    F A W Coumans
    Department of Medical Cell Biophysics, MIRA Research Institute, University of Twente, Enschede, The Netherlands
    Ann Oncol 21:1851-7. 2010
    ..We evaluated the association between these objects and survival in patients with prostate cancer...
  29. ncbi Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
    David R Shaffer
    Genitourinary Oncology Service, Immunicon Corporation, Huntingdon Valley, Pennsylvania, USA
    Clin Cancer Res 13:2023-9. 2007
    ..We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer...
  30. ncbi Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model
    Naoki Terada
    Department of Urology, Kyoto University Graduate School of Medicine, Kyoto 606 8507, Japan
    Cancer Res 70:1606-15. 2010
    More effective therapeutic approaches for castration-resistant prostate cancer (CRPC) are urgently needed, thus reinforcing the need to understand how prostate tumors progress to castration resistance...
  31. ncbi Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  32. ncbi Characterization of C4-2 prostate cancer bone metastases and their response to castration
    Jesco Pfitzenmaier
    Department of Urology, University of Washington, Seattle 98195, Washington, USA
    J Bone Miner Res 18:1882-8. 2003
    ..Here we describe characterization of a model consisting of direct injection of C4-2 cells into tibias...
  33. ncbi TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
    Stephane Oudard
    Hopital Europeen Georges Pompidou, Universite Paris Descartes, Paris 5, 20 rue Leblanc, Paris, France
    Future Oncol 7:497-506. 2011
    For patients with metastatic castration-resistant prostate cancer (mCRPC), the current standard of care is chemotherapy involving the tubulin-binding taxane docetaxel...
  34. ncbi Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer
    Giuseppe Lucarelli
    Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit Piazza Giulio Cesare 11, 70124 Bari, Italy
    Future Oncol 9:899-907. 2013
    ..In this study we assessed the role of serum sarcosine in metastatic castration-resistant prostate cancer (mCRPC) patients.
  35. pmc The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity
    Jianfei Qi
    Signal Transduction Program, Cancer Center, Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA
    Cancer Cell 23:332-46. 2013
    ..the mechanism underlying the regulation of the androgen receptor (AR), a central player in the development of castration-resistant prostate cancer (CRPC), holds promise for overcoming the challenge of treating CRPC...
  36. pmc Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
    Dana E Rathkopf
    Dana E Rathkopf, Michael J Morris, Josef J Fox, Daniel C Danila, Susan F Slovin, Mithat Gönen, Martin Fleisher, Steven M Larson, Charles L Sawyers, and Howard I Scher, Memorial Sloan Kettering Cancer Center Dana E Rathkopf, Michael J Morris, Josef J Fox, Daniel C Danila, Susan F Slovin, Steven M Larson, and Howard I Scher, Weill Cornell Medical College, New York, NY Jeffrey H Hager, Peter J Rix, Edna Chow Maneval, and Isan Chen, Aragon Pharmaceuticals, San Diego, CA and Charles L Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD
    J Clin Oncol 31:3525-30. 2013
    ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC)...
  37. ncbi Castration-resistant prostate cancer: adaptive responses in the androgen axis
    Alison Egan
    Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Cancer Treat Rev 40:426-33. 2014
    The androgen signaling axis in prostate cancer is associated with multiple adaptive mechanisms in response to castration. Herein we review these adaptations with an emphasis on recent molecular insights into the growth and development of ..
  38. ncbi Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Ann Oncol 24:1017-25. 2013
    ..phase III trial of abiraterone acetate and prednisone versus placebo and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel chemotherapy...
  39. ncbi New and emerging agents for the treatment of castration-resistant prostate cancer
    Celestia S Higano
    Department of Medicine, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Urol Oncol 29:S1-8. 2011
    ..prostate cancer (CaP) initially respond to androgen deprivation therapy but eventually develop metastatic castration-resistant prostate cancer (CRPC)...
  40. pmc Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer
    Virginie Baylot
    INSERM, UMR1068, Molecular Oncology Department, Marseille Cancerology Research Center, CRCM, Marseille, France
    Mol Ther 20:2244-56. 2012
    Heat shock protein 27 (Hsp27) is highly overexpressed in castration-resistant prostate cancer (CRPC) and an antisense inhibitor (OGX-427) is currently in phase II clinical trials...
  41. pmc Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
    Cancer 117:2077-85. 2011
    The natural history of castration-resistant nonmetastatic prostate cancer is poorly defined.
  42. ncbi Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
    Howard I Scher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Department of Medicine, Joan and Sanford I Weill College of Medicine, New York, New York 10021, USA
    Endocr Relat Cancer 11:459-76. 2004
    The categorization of prostate cancers that are progressing after castration as 'hormone-refractory' evolved from the clinical observation that surgical or medical castration (i.e...
  43. pmc Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
    G Attard
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 95:767-74. 2006
    b>Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality...
  44. pmc Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
    A Schayowitz
    Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Health Science Facility I, Room 580G, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Br J Cancer 103:1001-7. 2010
    ..and disease progression in prostate cancer (PCa), we investigated the relationship between the androgen receptor (AR) and mTOR pathways and the impact of inhibiting both pathways in androgen-dependent and castration-resistant PCa models.
  45. ncbi Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
    L R Molife
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Ann Oncol 21:109-13. 2010
    ..A phase II trial of the histone deacetylase inhibitor (HDACi) romidepsin was conducted in patients with progressing, metastatic, castration-resistant prostate cancer (CRPC).
  46. pmc A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006
    Joel Picus
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer 117:526-33. 2011
    ..Inhibition of vascular endothelial growth factor (VEGF) with bevacizumab may further enhance the antitumor effect of docetaxel and estramustine in patients with CRPC...
  47. ncbi Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine
    C Sumi
    Department of Pathology, Dartmouth Medical School, Hanover, New Hampshire 03756
    Cancer Res 49:2332-6. 1989
    ..b>Castration, ovariectomy, and s.c. implantations of either a 0.3-mg or a 1.0-mg 17 beta-estradiol (CAS:50-28...
  48. ncbi Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 117:517-25. 2011
    ..Elevated TIMP-1 levels have been associated with a poorer prognosis in multiple cancers...
  49. ncbi Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes
    Matthew D Galsky
    Division of Hematology and Medical Oncology, Department of Medicine, Director of Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    CA Cancer J Clin 62:299-308. 2012
    There have been more drugs approved by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer in the past 3 years than in the prior 3 decades, with additional drugs on the verge of approval based on ..
  50. ncbi Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature
    T Nelius
    Department of Urology, Texas Tech University Health Sciences Center, Lubbock, USA
    Cancer Treat Rev 37:444-55. 2011
    b>Castration-refractory prostate cancer remains a therapeutic challenge even after introduction of docetaxel as first-line treatment...
  51. pmc Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
    C Nabhan
    Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Br J Cancer 107:592-7. 2012
    Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients.
  52. pmc Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival
    Stephanie O Peacock
    University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Mol Endocrinol 26:1967-79. 2012
    ..or metastatic prostate cancer is treated by androgen deprivation; however, patients inevitably relapse with castration-resistant prostate cancer (CRPC)...
  53. pmc ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors
    Shinichi Yamashita
    Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neoplasia 14:74-83. 2012
    ..androgen receptor (AR) splice variants might contribute to the progression of prostate cancer (PCa) into castration resistance. However, the therapeutic strategy to target these AR splice variants still remains unresolved...
  54. ncbi Adaptation or selection--mechanisms of castration-resistant prostate cancer
    Yang Zong
    Medical Institute, University of California, Los Angeles, 675 Charles E Young Drive South, 5220 MRL Building, Los Angeles, CA 90095, USA
    Nat Rev Urol 10:90-8. 2013
    ..However, tumours relapse and develop into the lethal form of the disease, termed castration-resistant prostate cancer (CRPC)...
  55. pmc Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
    Isabel Heidegger
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    J Steroid Biochem Mol Biol 138:248-56. 2013
    Prostate cancer is a leading cause of cancer death in men in developed countries. Once the tumor has achieved a castration-refractory metastatic stage, treatment options are limited with the average survival of patients ranging from two ..
  56. ncbi Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma
    C Alberti
    L D of Surgical Semeiotics, Parma, Italy
    Eur Rev Med Pharmacol Sci 17:1658-64. 2013
    Challenges in the discovery of more potent agents to treat the castration-resistant prostate carcinoma (CRPC) reflect the frustrating condition due to development of its drug-resistance in addition to hormone-refractoriness...
  57. ncbi Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
    David I Quinn
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Lancet Oncol 14:893-900. 2013
    ..Atrasentan, an endothelin receptor antagonist, has shown activity in prostate cancer. We therefore assessed its effect on survival in patients with castration-resistant prostate cancer with bone metastases.
  58. pmc Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer
    Takashi Kobayashi
    Department of Urology, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto, Japan
    Int J Mol Sci 14:15615-35. 2013
    In the majority of castration-resistant prostate cancer (CRPC), prostate-specific antigen (PSA), product of a gene that is almost exclusively regulated by the androgen receptor (AR), still acts as a serum marker reflecting disease burden, ..
  59. pmc Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer
    Amir Goldkorn
    Amir Goldkorn, David I Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles Przemyslaw Twardowski, City of Hope, Duarte Philip C Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA Benjamin Ely and Catherine M Tangen, Southwest Oncology Group Statistical Center Celestia S Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA Louis M Fink, Nevada Cancer Institute Nicholas J Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV Peter J Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT Michael A Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD J Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH Ram H Datar and Richard J Cote, University of Miami Miller School of Medicine, Miami, FL Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, Kitakobayashi 880
    J Clin Oncol 32:1136-42. 2014
    ..CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer...
  60. ncbi Gonadectomy-induced adrenocortical neoplasia in the domestic ferret (Mustela putorius furo) and laboratory mouse
    M Bielinska
    Department of Pediatrics, Box 8208, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Vet Pathol 43:97-117. 2006
    ..Whether such genetic changes contribute to tissue susceptibility to neoplasia in neutered ferrets and mice awaits further study...
  61. ncbi Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Ann Oncol 20:1264-9. 2009
    This randomized, phase II study assessed the activity of oblimersen sodium, a Bcl-2 antisense oligonucleotide, administered before docetaxel (Taxotere) to patients with castration-resistant prostate cancer.
  62. ncbi Castration reduces the effect of serotonin-1A receptor stimulation on prepulse inhibition in rats
    Andrea Gogos
    Behavioural Neuroscience Laboratory, Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Behav Neurosci 117:1407-15. 2003
    ..Ovariectomized and sham-operated rats showed similar PPI in response to 8-OH-DPAT. These data suggest that the effect of 8-OH-DPAT on PPI in male rats depends on circulating hormone levels, particularly testosterone...
  63. ncbi Melatonin is as effective as testosterone in the prevention of soleus muscle atrophy induced by castration in rats
    Jale Oner
    Department of Histology and Embryology, Faculty of Veterinary Medicine, Mehmet Akif Ersoy University, Burdur, Turkey
    Anat Rec (Hoboken) 291:448-55. 2008
    ..The groups were arranged as sham, castrated, and testosterone- or melatonin-injected groups after castration. The soleus muscle samples were fixed in Bouin's solution for immunohistochemistry, and in 2...
  64. ncbi Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer
    Michele Lodde
    Department of Urology, Centre Hospitalier Universitaire du Québec, Quebec, Canada
    Urology 76:1189-93. 2010
    To evaluate the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in nonmetastatic castration-resistant prostate cancer patients and its impact on metastasis-free survival.
  65. ncbi Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo
    Takashi Kobayashi
    Department of Urology, Kyoto University, Graduate School of Medicine, Kyoto, Japan
    Mol Endocrinol 24:722-34. 2010
    ..Collectively, our present results both in vitro and in vivo highly implicate that Rac1 can be a potential therapeutic target for patients with advanced prostate cancer, especially those with castrate-resistant status...
  66. ncbi Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer
    Yuqiu Jiang
    Veridex, LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Clin Chem 56:1492-5. 2010
    ..from patients with advanced prostate cancer and represent a possible mechanism underlying the development of castration-resistant prostate cancer (CRPC)...
  67. pmc Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
    I Judson
    Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 90:2317-25. 2004
    ..Adrenocortical suppression may necessitate concomitant administration of replacement glucocorticoid...
  68. ncbi Activation of thymic regeneration in mice and humans following androgen blockade
    Jayne S Sutherland
    Department of Immunology, Monash University Medical School, Prahran, Victoria, Australia
    J Immunol 175:2741-53. 2005
    ..Collectively these studies represent a fundamentally new approach to treating immunodeficiency states in humans...
  69. pmc Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor
    R K Jain
    Edwin L Steele Laboratory, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 95:10820-5. 1998
    ..of the androgen-dependent Shionogi carcinoma grown in severe combined immunodeficient mice, we show that castration of these mice leads to tumor regression and a concomitant decrease in vascular endothelial growth factor (VEGF) ..
  70. pmc A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer
    Russell Szmulewitz
    The University of Chicago Medical Center, Chicago, United States
    Eur Urol 56:97-103. 2009
    Even in castration-resistant prostate cancer (CRPC), the androgen pathway remains biologically relevant. In preclinical models, androgen therapy for CRPC leads to growth arrest, apoptosis, and tumor shrinkage.
  71. pmc HE3235 inhibits growth of castration-resistant prostate cancer
    Theodore D Koreckij
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Neoplasia 11:1216-25. 2009
    ..However, most patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited...
  72. ncbi A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:1084-9. 2008
    To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites
  73. pmc A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer
    Jeremy Cetnar
    University of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical Research, Madison, WI 53705, USA
    Urol Oncol 31:436-41. 2013
    ....
  74. ncbi Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer
    M Merino
    Medical Oncology Department, University Hospital La Paz, Madrid, Spain
    Eur J Cancer 47:1846-51. 2011
    Despite multiple advances in prostate cancer therapy, treatment options for castration resistant disease are very limited...
  75. ncbi A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
    Young E Whang
    Division of Hematology Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Urol Oncol 31:82-6. 2013
    ..Lapatinib is an oral inhibitor of EGFR and HER-2. The objective of this study is to assess the preliminary clinical efficacy of lapatinib in the therapy of castration-resistant prostate cancer.
  76. ncbi Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer
    Kenji Tamura
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan
    Cancer Sci 100:914-9. 2009
    Prostate cancer is usually androgen-dependent and responds well to androgen ablation therapy based on castration. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype where they progress ..
  77. ncbi Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
    Raymond J Andersen
    Chemistry and Earth and Ocean Sciences, University of British Columbia, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1
    Cancer Cell 17:535-46. 2010
    b>Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity...
  78. pmc Developing imaging strategies for castration resistant prostate cancer
    Josef J Fox
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Acta Oncol 50:39-48. 2011
    ..The development and use of analytically valid imaging biomarkers will increase the likelihood of clinical qualification, and ultimately lead to improved patient outcomes...
  79. ncbi Changes in testosterone and dihydrotestosterone levels in male rat accessory sex organs, serum, and seminal fluid after castration: establishment of a new highly sensitive simultaneous androgen measurement method
    Bunzo Kashiwagi
    Department of Urology, Gunma University Graduated School of Medicine, Showa machi, Maebashi, Gunma 371 8511, Japan
    J Androl 26:586-91. 2005
    ..time course changes in testosterone and DHT levels in male accessory sex organs, serum, and seminal fluid after castration in rat models...
  80. ncbi Effects of castration, tooth resection, or tail docking on plasma metabolites and stress hormones in young pigs
    A Prunier
    UMR Veau et Porc, Institut National de la Recherche Agronomique, 35590 Saint Gilles, France
    J Anim Sci 83:216-22. 2005
    ..system or in the hypothalamo-pituitary-adrenal axis have been extensively used to evaluate pain induced by castration or tail docking in numerous species. Such data are missing in pigs...
  81. ncbi New agents for the management of castration-resistant prostate cancer
    Robert J Cersosimo
    Veterans Administration Medical Center, Boston, MA, USA
    Ann Pharmacother 46:1518-28. 2012
    To review the activity of 3 new agents approved for the management of advanced castration-resistant prostate cancer (CRPC): sipuleucel-T, cabazitaxel, and abiraterone acetate.
  82. ncbi Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement
    Xi De Wang
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 279:24733-44. 2004
    ..Furthermore, we found that Notch1 expression following castration and hormone replacement was concomitant with known basal cell markers p63 and cytokeratin 14 and was high in the ..
  83. ncbi A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
    K N Chi
    Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada
    Ann Oncol 23:53-8. 2012
    The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
  84. ncbi Effects of neonatal castration and androgenization on sexual dimorphism in bone, leptin and corticosterone secretion
    Wagner Garcez de Mello
    Multicentric Graduate Studies Program in Physiological Sciences, Brazilian Physiological Society Univ Estadual Paulista, SP, Brazil
    Bone 50:893-900. 2012
    ..b>Castration of males and androgenization of females were used as models to investigate the role of sex steroids shortly ..
  85. ncbi Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 105:1392-6. 2010
    ..the efficacy of the androgen-synthesis inhibitor ketoconazole as a secondary hormonal therapy in patients with castration-resistant prostate cancer (CRPC) previously treated with chemotherapy, as persistent androgens appear to play a ..
  86. ncbi Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues
    Seiji Arai
    Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
    Steroids 76:301-8. 2011
    The mechanism accounting for the development of castration-resistant prostate cancer (CRPC) remains unclear...
  87. pmc Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation
    Evan Y Yu
    Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
    J Clin Oncol 28:2668-73. 2010
    ..exploratory analysis of a trial of intermittent androgen deprivation (IAD) in men with biochemical relapse (BR) to establish first cycle characteristics prognostic for progression to castration-resistant prostate cancer (CRPC) and death.
  88. pmc TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable
    Jennifer S Davis
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Irvine, California 92697 4800, USA
    Mol Endocrinol 25:611-20. 2011
    ..magnetic resonance imaging to measure mouse prostate volume changes over time, we demonstrate that the extent of castration-induced prostate regression is significantly reduced in mice null for either the Tnf or Tnfr1 genes but not mice ..
  89. ncbi MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer
    Zhenwei Zhang
    Department of Medicine, NorthShore University Healthsystem, University of Chicago, 2650 Ridge Avenue, Evanston, IL 60201, USA
    Mol Cancer Ther 11:2410-8. 2012
    Almost all patients with advanced prostate cancer progress to castration-resistant stage with limited treatment options. Oncolytic adenoviruses have been actively pursued as potential agents for cancer treatment...
  90. pmc Castration-induced changes in mouse epididymal white adipose tissue
    Daniel Floryk
    Department of Genitourinary Medical Oncology Research, The University of Texas MD Anderson Cancer Center, Houston, USA
    Mol Cell Endocrinol 345:58-67. 2011
    We analyzed the effects of castration on epididymal white adipose tissue (WAT) in C57BL/6J mice which were fed a regular or high-fat diet...
  91. ncbi Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
    Jennifer A Locke
    The Prostate Centre at Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, British Columbia, Canada
    J Steroid Biochem Mol Biol 115:126-36. 2009
    In castration-resistant prostate cancer (CRPC) many androgen-regulated genes become re-expressed and tissue androgen levels increase despite low serum levels...
  92. ncbi Levels of serum steroids, aromatase activity, and estrogen receptors in preoptic area, hypothalamus, and amygdala of B6D2F1 male house mice that differ in the display of copulatory behavior after castration
    K Sinchak
    Department of Zoology, Michigan State University, USA
    Behav Neurosci 110:593-602. 1996
    Most male B6D2F1 hybrid house mice continue to copulate after castration (continuers), whereas others do not (noncontinuers). Copulation in continuers appears estrogen dependent...
  93. ncbi Sorbitol dehydrogenase expression is regulated by androgens in the human prostate
    Zoltan Szabo
    Department of Pathology, University of Oulu, Oulu, Finland
    Oncol Rep 23:1233-9. 2010
    ..Androgens are essential for the development of prostate cancer. We studied castration-induced gene expression changes in the human prostate using the GeneChip array, and identified SORD as being ..
  94. ncbi A passion for castration: characterizing men who are fascinated with castration, but have not been castrated
    Lesley F Roberts
    Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia, Canada
    J Sex Med 5:1669-80. 2008
    A number of men have extreme castration ideations. Many only fantasize about castration; others actualize their fantasies.
  95. ncbi Contemporary management of metastatic castration-resistant prostate cancer
    Guru Sonpavde
    Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA
    Curr Opin Urol 21:241-7. 2011
    This review will describe the contemporary management of castration-resistant prostate cancer in the context of multiple recent advances.
  96. pmc Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer
    Natalia V Narizhneva
    Anti Cancer Drug Discovery Department, Cleveland BioLabs, Inc, Buffalo, NY, USA
    Cell Cycle 8:4155-67. 2009
    ..Indeed, several of the identified AR inhibitors demonstrated in vivo efficacy in mouse models of PCa and are candidates for pharmacologic optimization...
  97. ncbi Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 8:994-1000. 2007
    ..We aimed to assess whether combining estramustine with chemotherapy increases survival in patients with castration-refractory prostate cancer.
  98. ncbi Castration inhibits exercise-induced accumulation of Hsp70 in male rodent hearts
    K J Milne
    School of Kinesiology, Faculty of Health Sciences, University of Western Ontario, London, ON, Canada N6A 3K7
    Am J Physiol Heart Circ Physiol 290:H1610-6. 2006
    ..Because androgen receptors are expressed in the heart and castration leads to decreases in calcium regulatory proteins and altered cardiac function, testosterone (T) or its ..
  99. ncbi Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy
    Guru Sonpavde
    Texas Oncology and Baylor Sammons Cancer Center, Dallas, TX, USA
    Clin Genitourin Cancer 6:134-7. 2008
    Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy...
  100. ncbi Castration has antihypertensive and organoprotective effects in male but not in female heterozygous Ren-2 rats
    Ivana Vaneckova
    Center for Experimental Medicine, Charles University, Prague, Czech Republic
    Kidney Blood Press Res 34:46-52. 2011
    ..We assessed the effect of castration on BP and organ damage, as well as angiotensin II (ANG II), estradiol and testosterone levels in heterozygous ..
  101. ncbi Changes of pituitary and penile structure in male adult rats following castration and high-fat diet
    Y L Lu
    Endocrinology and Metabolism Research Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People s Hospital Affiliated Shanghai Jiaotong University School of Medicine, Shanghai, China
    J Endocrinol Invest 34:111-6. 2011
    ..To investigate the influence of low androgen levels and high-fat diet on the structure of pituitary and penis in male rats...

Research Grants72

  1. INTEGRATION OF CHEMOSENSORY AND HORMONAL STIMULI
    Ruth Wood; Fiscal Year: 2006
    Gonadal steroid hormones are essential for mating in male hamsters, as in most mammals. Castration also reduces sexual motivation, as measured by interest in vaginal odors and preference for a receptive female...
  2. Epistasis in Steroidogenic Genes in the Prediction of Alzheimer's Disease
    CRAIG STEPHEN ATWOOD; Fiscal Year: 2013
    ..controlled studies), 3) the abrupt cognitive deficits observed in premenopausal women following 'chemical castration', deficits that are reversible with simultaneous administration of E2, 4) the increased risk of dementia in ..
  3. Endothelin-1 and androgen in prostate cancer bone metastasis and bone health
    Gregory A Clines; Fiscal Year: 2013
    ..Aim 2 will test how the ETAR antagonist zibotentan combined with castration effects tumor expansion in bone, osteosclerosis and angiogenesis in a model of prostate cancer bone metastasis...
  4. Epigenetic Regulation Of Sex-dependent Liver Cancer
    Arlin B Rogers; Fiscal Year: 2012
    ..others have shown that male HCC susceptibility is maturationally imprinted, as there is a decreasing benefit of castration with advancing age. Liver masculinization is enacted by pulsatile growth hormone from the pituitary...
  5. Amoeboid Membrane Dynamics in Prostate Cancer
    Michael R Freeman; Fiscal Year: 2013
    ..Prostate adenocarcinoma (PCa) is a leading cause of death from cancer and there is no effective treatment for "castration-resistant" disease...
  6. GENDER DIFFERENCES IN STIMULANT ACTION
    Cynthia M Kuhn; Fiscal Year: 2012
    ..Ovariectomy causes a significant fall in DA neuron number, while castration of males results in a surprising increase in cell number...
  7. Identification of stromal responses during castration-induced thymic regrowth.
    Howard T Petrie; Fiscal Year: 2013
    ..Notably, the thymus can be induced to completely regrow, although the most efficient means for this (surgical castration) is somewhat impractical...
  8. Attenuation of androgen deprivation therapy-induced metabolic syndrome by diet
    Oleg Varlamov; Fiscal Year: 2013
    ..To test this hypothesis, we will determine whether surgical castration of middle-aged males increases the risk and the magnitude of HFD- induced insulin resistance and obesity...
  9. Identification of Stromal Responses During Castration Mediated Thymic Regrowth
    ANN VENABLES GRIFFITH; Fiscal Year: 2011
    ..Notably, the thymus can be induced to completely regrow, but the most efficient means for this (surgical castration) is impractical...
  10. Interactions of MAO A with vulnerability factors for aggression
    Marco Bortolato; Fiscal Year: 2012
    ..and 5AR in the aggression of MAO A-deficient mice, by assessing the behavioral and molecular changes induced by castration and finasteride treatment...
  11. Low birth weight, the kidney, and hypertension
    Barbara T Alexander; Fiscal Year: 2013
    ..Importantly, castration abolishes hypertension in male IUGR;ovariectomy (OVX) induces a marked increase in blood pressure (BP) in female ..
  12. Mechanisms for the Transition to Castrate Resistant Prostate Cancer
    Stephen R Plymate; Fiscal Year: 2013
    ..Mechanisms for the transition to Castrate Resistant Prostate cancer Hypothesis: Following castration there is a decrease in prostate tumor volume and progression in animal models and human disease...
  13. Loss of Filamin A Nuclear Localization in Prostate Cancer Progression
    Paramita M Ghosh; Fiscal Year: 2013
    ..receives hormonal treatment which is initially effective, but frequently fail indicative of the development of castration resistant prostate cancer (CRPC)...
  14. Mechanism-based Classification and Targeting of Castration-Resistant Prostate Can
    PETER S contact NELSON; Fiscal Year: 2010
    ..cancer progression are complex, for clarity and simplicity this clinical state is more accurately classified as Castration Resistant Prostate Cancer (CRPC)...
  15. Axon, Testosterone and Mental Health during Adolescence
    Tomas Paus; Fiscal Year: 2013
    ..This aim will be achieved by studying male rats following real or sham castration, with or without supplementation of testosterone...
  16. A Novel Synthetic Androgen Receptor Antagonist
    Zhongyun Dong; Fiscal Year: 2012
    ..He will determine and compare effects of DL3 and Bical, alone or in combination with castration, on growth of tumors formed by both androgen-dependent and -independent cells and by cells refractory to Flut...
  17. Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer
    Allen C Gao; Fiscal Year: 2013
    ..in prostate cancer KEYWORDS (MeSH terms only;minimum three) Prostate cancer, androgen receptor, RhoGDI, castration-resistance, proliferation BRIEF STATEMENT OF RESEARCH OBJECTIVES (Do not use continuation sheets) Treatment for ..
  18. Regulation of androgen receptor activity in prostate cancer cells in an aged mous
    STEPHANIE OLGA PEACOCK; Fiscal Year: 2013
    ..One of the most common therapies for advanced prostate cancer is androgen deprivation via chemical or physical castration. Unfortunately, most patients relapse and continue to experience debilitating bone pain, urinary symptoms, and ..
  19. Prevention of Prostate Cancer by Sulforaphane
    Shivendra Singh; Fiscal Year: 2013
    ..in TRAMP mice without any toxicity, and SFN treatment suppresses cellular pathways implicated in emergence of castration-resistant prostate cancer (CRPC)...
  20. Steroid Receptors and Transcriptional Control of Thymic Rebound
    Nancy R Manley; Fiscal Year: 2011
    ..that has been well-documented is the role of androgen depletion in inducing rebound - surgical or chemical castration in humans or mice induces at least transient thymic recovery and increased T cell production, and deletion of ..
  21. New treatment for androgen sensitive and resistant prostate cancer
    Angela M Brodie; Fiscal Year: 2013
    ..In LAPC4 human prostate cancer xenografts, tumor growth was inhibited to a greater extent by VN/124-1, than by castration, the clinically used antiandrogen bicalutamide or abiraterone at equivalent doses...
  22. Regulation of androgen receptor function by H3K4 methylation in prostate cancer
    Qianben Wang; Fiscal Year: 2013
    ..cancer Project Summary The evolution of prostate cancer from an androgen-dependent state (ADPC) to one that is castration- resistant (CRPC) marks the lethal progression of the disease...
  23. Chemoprevention of prostate cancer by Allspice derived polyphenol: Ericifolin
    Bal L Lokeshwar; Fiscal Year: 2013
    ..of antitumor action of EF using molecular, cellular and genetic approaches in both androgen-dependent and castration resistant prostate cancer cells;3...
  24. Molecular basis of androgen receptor mediated gene transcriptional repression
    Changmeng Cai; Fiscal Year: 2013
    ..This form of cancer is called castration resistant prostate cancer, or CRPC...
  25. New type of androgen receptor inhibitors for prostate cancer treatment
    Olga B Chernova; Fiscal Year: 2010
    ..be used alone or in combination with standard of care;(ii) they supposed to be active against PC resistant to castration, hormone withdrawal, chemo- and radiotherapy;(iii) they are specifically targeted against AR expressing PC cells ..
  26. Vitamin D Analogs for Chemoprevention of Prostate Cancer
    Barbara A Foster; Fiscal Year: 2012
    ..We propose a model in which VDR corepressor increases during prostate cancer progression and in castration recurrent disease, resulting in repression of VDR mediated gene transcription...
  27. Test to Predict Effectiveness of Docetaxel Treatment
    Carol Swartz; Fiscal Year: 2013
    The overall goal of this project is to develop better screening methods to provide castration-resistant prostate cancer patients with more appropriate chemotherapeutic agents...
  28. Role of Androgen Receptor Phosphorylation in Prostate Cancer
    Daniel G Gioeli; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: There are no effective treatments for castration-resistant metastatic prostate cancer...
  29. Gender Disparity in Bladder Cancer and Chemopreventive Intervention
    Yuesheng Zhang; Fiscal Year: 2013
    ..Comparison will also be made between mice with and without castration. Another carcinogen 2- acetylaminofluorene (2-AAF) will be used to rule out ABP-specific effects...
  30. Elucidating a novel molecular biomarker for castration-resistant prostate cancer
    Nima Sharifi; Fiscal Year: 2013
    ..Metastatic disease almost invariably recurs as castration-resistant prostate cancer (CRPC), which is the lethal form of this disease...
  31. Ovariectomy Induced T Cell Inflammatory Cytokines/Bone Loss in Young & Old Mice
    Roberto Pacifici; Fiscal Year: 2010
    ..Both aging and castration decrease immune tolerance...
  32. Molecular Mechanisms of Hormone-independence of Prostate Cancer
    Yun Qiu; Fiscal Year: 2013
    ..AR3 may play a distinct, yet essential, role in castration-resistant growth through regulating a unique set of genes which are not regulated by the prototype AR...
  33. Mechanism of promiscuous AR activation in PTEN-mutated prostate cancer
    Haojie Huang; Fiscal Year: 2013
    ..a majority of tumors invariably relapse and become a disease called androgen-deprivation independent or castration-resistant prostate cancer (CRPC), from which most patients eventually die...
  34. Modulation of Apoptosis in Prostate Cancer
    Khalil Ahmed; Fiscal Year: 2013
    ..This form of the disease is termed castration resistant PCa (CRPC) and is generally fatal...
  35. Interleukin-6 and castration-resistant prostate cancer
    Allen C Gao; Fiscal Year: 2013
    ..However, CaP eventually continues to grow in an androgen-independent or castration-resistant state...
  36. Androgen Receptor in B Cell Development and Functions
    Chawnshang Chang; Fiscal Year: 2010
    Sex hormones are linked to regulation of immune and inflammatory responses. Castration of male mice results in expansion of B lymphocytes in the bone marrow and peripheral blood...
  37. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
    Estuardo Aguilar-Cordova; Fiscal Year: 2013
    ..each year 60,000-100,000 men develop prostate cancer recurrence for which they receive surgical or pharmacologic castration, a life extending but non-curative therapy. Castration negatively impacts quality of life...
  38. Non-AR mediated DHT-promoted Bladder Cancer initiation and progression
    Chawnshang Chang; Fiscal Year: 2013
    ..dependent and therefore it is not assumed that androgen deprivation therapy (ADT) with chemical or surgical castration can be an effective treatment option for BCa patients in order to repress tumor progression...
  39. Autoimmunity and age-related changes in thymic induction of self-tolerance.
    Howard T Petrie; Fiscal Year: 2013
    ..regenerative potential, and can be completely regrown (albeit transiently) using stimuli such as surgical castration. In the same study mentioned above, we showed that most of the affects of aging on the thymus, including the ..
  40. (PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resist
    Allen C Gao; Fiscal Year: 2013
    ..prostate cancer patients develop resistance to hormone deprivation therapy within three years and progress to castration resistant prostate cancer (CRPC), and become metastatic...
  41. ARF GTPase regulation of prostate tumorigenesis: spheroid and in vivo approaches
    DAVID MICHAEL BRYANT; Fiscal Year: 2013
    ..Next, he will elucidate the interplay between the ARF regulome and oncogenic pathways leading to castration-resistant prostate cancer (Aim 2)...
  42. Prostate Cancer: Transition to Androgen - Independence (CA77739)
    James L Mohler; Fiscal Year: 2013
    ..Project 1 will pursue the elimination ofAR transcriptional activity during the post-castration period using strategies that prevent the synthesis of androgen, cause the degradation of AR ligands or their ..
  43. Modeling E2F3 isoform specificity in prostate cancer
    Maria Mudryj; Fiscal Year: 2013
    ..Androgen ablation therapy is initially successful, but relapses occur due to the development of castration resistant prostate cancer (CRPC)...
  44. THE ROLE OF TROP2 IN PROSTATE STEM CELL BIOLOGY AND TUMORIGENESIS
    LOREN SCOTT MICHEL; Fiscal Year: 2013
    ..the regenerative potential of Trop2 null prostate tissue and in vivo and ex vivo and analyze its structure after castration and testosterone-induced regrowth...
  45. Defining the role of eIF4F in metastatic castration resistant prostate cancer
    ANDREW CALEB HSIEH; Fiscal Year: 2013
    ..Since the PI3K-AKT-mTOR and MYC pathways are both deregulated in lethal metastatic castration resistant prostate cancer (CRPC), he hypothesizes that these pathways converge on eIF4F to elicit the aberrant ..
  46. A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer
    Khalil Ahmed; Fiscal Year: 2013
    ..achieve only partial disease stabilization, and no truly curative approaches are available for the lethal castration resistant prostate cancer...
  47. Nanomicellar Formulation for Synergistic Targeting of Prostate Cancer
    Song Li; Fiscal Year: 2013
    ..Although majority of patients with metastatic PCa initially respond to chemical or surgical castration, a significant number will eventually advance to hormone-refractory PCa (HRPC), for which effective treatment is ..
  48. IKK <alpha>and the Control of Prostate Cancer Metastasis
    Michael Karin; Fiscal Year: 2013
    ..and immune mechanisms in the control of metastatic progression in prostate cancer (PCa) and the development of castration-resistant tumors after androgen ablation...
  49. Transgenic Animal Models for Prostate Cancer
    Robert J Matusik; Fiscal Year: 2012
    ..activation of NF- ?B in the mouse prostate is sufficient to prevent regression of the prostate following castration by maintaining extremely high levels of nuclear AR and continued epithelial cell proliferation...
  50. Pten-loss Dysregulated Pathways in Prostate Cancer
    Zhenbang Chen; Fiscal Year: 2013
    ..Molecular mechanisms leading to the initiation and progression of PCa including castration resistant prostate cancer (CRPC) or androgen insensitive prostate cancer (AI-PC) are poorly understood...
  51. Cooperative steroidogenic inhibition for treatment of advanced prostate cancer
    Nima Sharifi; Fiscal Year: 2013
    ..Unfortunately, metastatic disease almost always recurs as castration-resistant prostate cancer (CRPC), which is generally the lethal form of this disease...
  52. Decoding NanogP8 in Tumorigenesis
    Dean G Tang; Fiscal Year: 2013
    ..is sufficient to confer CSC properties, enhances tumor regeneration, and, significantly, promotes development of castration-resistant PCa or CRPC...
  53. The Role of NOV (CCN3) in Prostate Cancer Progression
    Jindan Yu; Fiscal Year: 2013
    ..Interestingly, in the late-stage castration-resistant PCa (CRPC), AR has become activated, rather than insensitive, in a low androgen environment, thus ..
  54. Developing Fisetin for the Managment of Prostate Cancer
    Hasan Mukhtar; Fiscal Year: 2013
    ..1/Pten mouse model of prostate cancer and 3) investigate the efficacy of fisetin against castration induced androgen independent adenocarcinoma in the Nkx3.1/Pten mutant mouse model of advanced prostate cancer...
  55. Immune-inflammatory signaling and hormone-refractory prostate cancer evolution.
    Jun Li Luo; Fiscal Year: 2013
    ..NF-?B, the principle inflammatory transcription factor, in immune cells, dramatically impairs the development of castration resistant prostate cancer (CR-PCa) in both transgenic and xenograft PCa mouse models...
  56. Role of Oncogenic Kinase Pim-1 in Prostate Cancer
    Sarki A Abdulkadir; Fiscal Year: 2013
    ..e. castration-resistant prostate cancer)...
  57. Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
    Matthew B Rettig; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Castration resistant prostate cancer (CRPC) is an incurable disease for which novel and effective therapies are critically needed...
  58. STRESS INDUCTION OF GLUCOSE REGULATED PROTEIN GRP78/BiP
    Amy S Lee; Fiscal Year: 2013
    ..cancer model which allows bioluminescence monitoring of cancer development, progression and recurrence after castration. Castration sensitive and resistant cells derived from this model will also be studied...
  59. Advanced Development of An Integrated CTC Enrichment Technology
    Hsian Rong Tseng; Fiscal Year: 2013
    ..Enumeration of CTCs has established clinical utility in patients with metastatic, castration-resistant (CR;i.e...
  60. Targeted Radiotherapy/Chemotherapy Treatment of Prostate Cancer
    Timothy J Hoffman; Fiscal Year: 2013
    ..evaluate the efficacy of a novel multi-modal tumor treatment regimen on overall survival in models of metastatic castration resistant prostate cancer (mCRPC)...
  61. Paxillin as a Liaison between Extranuclear and Intranuclear Steroid Signaling
    Stephen R Hammes; Fiscal Year: 2013
    ..paxillin's actions in the nucleus while sparing it's actions in the cytoplasm, thereby using nuclear paxillin as a target for the treatment of both castration-sensitive and castration-resistant prostate cancer growth.
  62. Progenitor cells of the mouse prostate epithelium
    Michael M Shen; Fiscal Year: 2013
    ..period, we have used genetic lineage-tracing to identify a prostate epithelial stem cell population, termed castration-resistant Nkx3...
  63. AR Gene Rearrangements and AR Signaling in Prostate Cancer
    Scott M Dehm; Fiscal Year: 2013
    ..to AR-targeted therapy is variable, and all patients will ultimately develop resistance and progress to a castration-resistant form of the disease associated with morbidity and death...
  64. PARASITIC CASTRATION IN SNAILS--ROLE OF BIOGENIC AMINES
    TIMOTHY YOSHINO; Fiscal Year: 1999
    DESCRIPTION: (Adapted from the Applicant's Abstract): Parasitic castration of snails by larval trematodes, which manifests itself as histopathological changes in the gonads and/or lowered oviposition, represents one of the most dramatic ..
  65. ENVIRONMENTAL SEX DETERMINATION AND DIFFERENTIATION
    David Crews; Fiscal Year: 1991
    ..temperature organizes adult sexuality will be studied through hormonal manipulations of embryos and neonates by castration and/or administration of steroid hormones, synthetic hormone agonists and antagonists, enzyme inhibitors, and ..
  66. EFFECT OF CASTRATION+/-ESTROGEN ON THE CORPUS CAVERNOSUM
    Gregory Broderick; Fiscal Year: 1993
    ..Many studies which utilize human corpus cavernosum obtain the tissue from transsexual males who have undergone castration and extended estrogen therapy...
  67. PROSTATE CANCER GENE THERAPY WITH RECOMBINANT VACCINES
    Martin Sanda; Fiscal Year: 1999
    ..To augment recombinant vaccine efficacy in treating advanced tumor burden, castration will be used both to mitigate oncogene-specific tolerance and to reduce host tumor cell burden...
  68. GnRH Gene Expression in the Ovary
    Helen Kim; Fiscal Year: 2009
    ..hormone (GnRH) agonists are frequently used to down-regulate hypothalamic GnRH and produce "chemical castration." More recently, GnRH antagonists, which block the GnRH receptor, have been used for pituitary suppression in ..
  69. Immunologic Effects of Lactation on HIV infected women
    Grace Aldrovandi; Fiscal Year: 2006
    ..Estrogen and other sex steroids have long been recognized as negative regulators of thymopoiesis. For example, castration of male or female rats increases thymic size, CD4 counts and the number of peripheral blood naive T cells...
  70. Cocaine Abuse and the Role of Gonadal Steroid Hormones
    NANCY MELLO; Fiscal Year: 2005
    ..in an own-control design across gonadal steroid treatment conditions, and before and after ovariectomy and castration. In normally cycling females, the influence of changing steroid hormone levels across the menstrual cycle will ..
  71. Gender Influence in Mice with Myocardial Infarction
    Xiao Ping Yang; Fiscal Year: 2009
    ..Supplementation of estrogen and/or castration in males reduced the rupture rate and slowed LV remodeling, while supplementation of testosterone in females ..
  72. Sex steroids and the thymus
    GILBERT KERSH; Fiscal Year: 2006
    A relationship exists between the gonads and the thymus. Castration results in a significant increase in the size of the thymus, and elevated serum levels of sex hormones results in a significant decrease in the size of the thymus...